Detail of the clinical trial
| Title of the trial | Immune Response to Influenza Vaccine in Subjects with B-cell Malignancies Treated with Idelalisib |
|---|---|
| EudraCT number | 2017-003055-30 |
| Protocol number | GS-US-313-4100 |
| Sponsor | Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States of America |
| Indications | Hemato-oncology |
| Diagnosis | Influenza Vaccine / Idelalisib |
| Population in clinical trial |
Adults (18-65 years) Elderly ( > 65 years) Male Female Patients |
| Year of receiving the request to Institute (SÚKL) | 2018 |
| Date of approval by Institute (SÚKL) | 13..6.2018 |
| Date of approval by EC | 6.6.2018 |
| Date of initiation CT in ČR | 27.12.2018 |
| Date of ending CT in ČR | 23.10.2019 |
| Notice | |
| Sites |
Fakultní nemocnice v Motole,Onkologická klinika,V Úvalu 84,Praha 5-Motol,150 06 Fakultní nemocnice Královské Vinohrady,Interní hematologická klinika,Šrobárova 1150/50,Praha 10,100 34 |
cz